RAPS

Groups suggest tweaks to FDA’s guidance on developing drugs to treat radiation exposure

Stakeholders urged the US Food and Drug Administration (FDA) to broaden the scope of its guidance on developing drugs for acute radiation syndrome (ARS) to treat downstream exposure, while one group ...
Business Wire

Humanetics Advances Development of Novel Radiation Protection Drug With New Study Results

MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation (Humanetics) announced the publication of two noteworthy manuscripts detailing the development of BIO 300 as a radioprotective agent against acute ...
Business Wire

Synedgen Announces $2.2 Million JWMRP Award for MIIST305 For Use as a Prophylactic Radiation Medical Countermeasure

CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced that it has been awarded a $2.2 million ...
Nasdaq

Pluri Evaluates Mass Production Of PLX-R18 For Acute Radiation Syndrome Amid Nuclear Threats

(RTTNews) - Pluri Inc. (PLUR), a biotechnology company specializing in cell-based solutions, announced on Monday that it is assessing its readiness to initiate mass production of PLX-R18, a potential ...
Medscape

Exceptional Use Recommendation for Nuclear Emergency Drug

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an exceptional circumstances marketing authorization for Imreplys. The drug — active ...